Dolutegravir/lamivudine/tenofovir disoproxil fumarate - Aurobindo Pharma
Latest Information Update: 22 Oct 2020
Price :
$50 *
At a glance
- Originator Aurobindo Pharma
- Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Phosphonic acids; Purines; Pyrimidine nucleosides; Small molecules
- Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 05 Oct 2017 Chemical structure information added
- 21 Aug 2017 Aurobindo Pharma intends to launch dolutegravir/lamivudine/tenofovir disoproxil fumarate tablets in sub-Saharan Africa in 2018
- 21 Aug 2017 FDA issues tentative approval to dolutegravir/lamivudine/tenofovir disoproxil fumarate (50 mg/300 mg/300 mg) tablets for the treatment of HIV-1 infections (In adults, In adolescents) in USA